IMEXF (Imagin Medical) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


What is Imagin Medical Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Imagin Medical's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

IMEXF vs ABT, SYK, MDT: Margin of Safety % (DCF FCF Based) Comparison

For the Medical Devices subindustry, Imagin Medical's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imagin Medical Margin of Safety % (DCF FCF Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Imagin Medical's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Imagin Medical's Margin of Safety % (DCF FCF Based) falls into.


Imagin Medical Business Description

Address 890 West Pender Street, Suite 600, Vancouver, BC, CAN, V6C 1J9
Imagin Medical Inc is a Urologic Oncology company developing technologies to visualize and treat urologic cancers, including bladder and prostate cancer, through minimally invasive surgery. The company's first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting bladder cancer, helping to improve the surgical management of this disease. Imagin's follow-on product, the enCAGE Coil is a device with 510(k) clearance for soft tissue ablation. Imagin intends to refine the disposable bipolar radio frequency-based probe for use in the treatment of prostate cancer and benign prostate hypoplasia (BPH) and submit appropriate FDA premarket applications for the new indications.